P184 Patient reported impact and satisfaction with guselkumab and IL-17 inhibitors in psoriatic arthritis: 12-month results of the PsABIOnd observational study

Abstract Background/Aims Increased patient treatment satisfaction may improve therapeutic adherence and long-term outcomes. The efficacy of targeted drugs in psoriatic arthritis (PsA), including clinical and patient-reported outcomes (PROs), has been demonstrated in randomised controlled trials; however, real-world data are scarcer, particularly for IL-23 and IL-17 inhibitors (i). This analysis aimed to assess PsA PROs and patient satisfaction with guselkumab (GUS) and IL-17i treatment at 12 months. Methods PsABIOnd (NCT05049798) is an ongoing, global, observational, study in PsA patients starting GUS or IL17i as 1st to-4th line of biologic therapy per standard of care.1 In this interim analysis, PsABIOnd participants with a baseline and ≥1 follow-up assessment through the 12-month visit (+/ 3 months) were analysed according to their initial treatment, regardless of later switches. Patient-reported impact was assessed with the PsA Impact of Disease-12 (PsAID12; 0-10) questionnaire and patient global assessment of PsA activity (PtGA; 0-100 VAS). Mean changes from baseline to 12 months in PsAID-12 total score and PtGA, and proportions of participants achieving PsAID-12 minimal clinically important improvement (MCII; improvement ≥1.4) were determined. Patient satisfaction with treatment was descriptively assessed with mean scores (0-100; higher being better) in effectiveness, convenience, and global satisfaction domains of the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)2 and with proportions of participants rating their well-being as improved and symptoms as acceptable using the Patient Acceptable Symptom State (PASS) scale.3 No statistical comparisons were performed. Results A total of 511 and 504 participants received GUS or IL-17i, respectively, as initial treatment. Sex (60.7%/59.7% female), prior targeted drug use (62.6%/62.9%), and mean age (53.0/53.7 years), PsAID-12 total score (5.1/5.1), and PtGA (59.4/60.7) were comparable for GUS/IL-17i at baseline. At the 12-month visit, mean changes from baseline in PsAID-12 total score (-1.6/-1.7) and in PtGA (-17.0/- 19.1), and rates of participants achieving PsAID-12 MCII (56.8%/53.7%) were similar with GUS and IL-17i. Patient satisfaction with GUS vs IL-17i at the 12-month visit was high, with similar proportions of participants rating their overall well-being as better (57.7%/64.9%) and in an acceptable state (61.0%/64.2%), and comparable mean TSQM-9 scores across domains (61.8/63.8). Conclusion By 12 months of treatment, clinically meaningful improvements in multidomain PROs and high levels of satisfaction were seen in participants treated in real-world with GUS or IL-17i, with the majority reporting achievement of acceptable state. These results may aid shared treatment decision-making by facilitating discussions on patient expectations.References:1. Siebert S, et al. Rheumatol Ther. 2023;10(2):489-5052. Atkinson MJ, et al. Health Qual Life Outcomes. 2004;2:123. Tubach F, et al. Arthritis Rheum. 2006;55(6):960-3 Disclosure L. Gossec: Consultancies; AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Johnson AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Johnson AbbVie, Biogen, Eli Lilly, Novartis, UCB. M. Sharaf: Corporate appointments; Johnson Johnson Abbvie, Chugai, Eli Lilly, Johnson Abbvie, Chugai, Eli Lilly, Johnson AbbVie, Chugai, Eli Lilly, Johnson AbbVie, Eli Lilly, Johnson Abbvie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Daichii-Sankyo, Eisai, Eli Lilly, Gilead, Johnson Abbvie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Daichii-Sankyo, Eisai, Eli Lilly, Gilead, Johnson Abbvie, Amgen, Celgene, Johnson Abbvie, Amgen, Celgene, Johnson Abbvie, Johnson Abbvie, Amgen, Eli Lilly, GSK, Johnson JSS Medical Research. Consultancies; Johnson IQVIA. Consultancies; Johnson Johnson Johnson Galapagos. E. Soriano: Consultancies; Abbvie, Johnson Abbvie, Johnson Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson AbbVie, Johnson Abbvie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson Abbvie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson Johnson Meeting attendance/travel support: Johnson AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Genzyme, Gilead, Johnson AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Genzyme, Gilead, Johnson Celgene, Chugai, Johnson AbbVie, Amgen, AstraZeneca, Johnson AbbVie, Amgen, AstraZeneca, Johnson AbbVie, Amgen, Johnson Eli Lilly, GSK, Johnson & Johnson, Pfizer, UCB.